BioSpace News Archive

Duchesnay Inc., member of Duchesnay Pharmaceutical Group (DPG) one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, has recently filed a New Drug Submission (NDS) to Health Canada for its segesterone acetate / ethinyl estradiol slow-release vaginal system developed for contraception control.

TScan Therapeutics, Inc. announced it has been named one of the Top Places to Work in Massachusetts in the 16th annual employee-based survey project from The Boston Globe.

Tiziana Life Sciences Ltd. announced that the company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis in the Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access Program.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen.

Nanoscope Therapeutics Inc. today announced that Jared Stephens , PhD, Vice President of Strategy and Business Development, will present at the 13th Annual Ophthalmology Innovation Summit (OIS) taking place from December 1-2 in San Diego, California.

SciNeuro Pharmaceuticals today announced the completion of dosing in its Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study.

SOPHiA GENETICS announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France.

Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, has announced the FDA clearance of its microcatheter designed for the precise delivery of a broad range of embolic agents.

Precision BioSciences, Inc. today announced that the company will present at Hep-DART 2023 in an industry session and host a poster presentation on December 5, 2023, in Los Cabos, Mexico.

Lexicon Pharmaceuticals, Inc. today announced that it has enrolled the first patient in PROGRESS (A Phase 2b, Dose-ranging, Randomized, Double-blind, PlacebO-controlled, Parallel-GRoup, MulticEnter Study with an Open-label Extension in PatientS with Diabetic Peripheral Neuropathic Pain) studying LX9211, a potent, orally-delivered, selective, investigational small molecule inhibitor of adaptor-associated kinase 1 (AAK1).